{"id":"https://openalex.org/W2587422896","doi":"https://doi.org/10.1182/blood.v124.21.910.910","title":"Bone Marrow Stroma Protects BCR-ABL-Negative Myeloproliferative Neoplasms from Ruxolitinib- and Vorinostat-Induced Apoptosis","display_name":"Bone Marrow Stroma Protects BCR-ABL-Negative Myeloproliferative Neoplasms from Ruxolitinib- and Vorinostat-Induced Apoptosis","publication_year":2014,"publication_date":"2014-12-06","ids":{"openalex":"https://openalex.org/W2587422896","doi":"https://doi.org/10.1182/blood.v124.21.910.910","mag":"2587422896"},"language":"en","primary_location":{"id":"doi:10.1182/blood.v124.21.910.910","doi":"https://doi.org/10.1182/blood.v124.21.910.910","is_oa":false,"landing_page_url":"https://doi.org/10.1182/blood.v124.21.910.910","pdf_url":null,"source":{"id":"https://openalex.org/S200071133","display_name":"Blood","issn_l":"0006-4971","issn":["0006-4971","1528-0020"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Blood","raw_type":"journal-article"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5034784560","display_name":"Bruno A. Cardoso","orcid":"https://orcid.org/0000-0002-6521-7257","observed_orcids":["https://orcid.org/0000-0002-6521-7257"]},"institutions":[{"id":"https://openalex.org/I4210103180","display_name":"Instituto Portugu\u00eas de Oncologia Francisco Gentil","ror":"https://ror.org/00r7b5b77","country_code":"PT","type":"healthcare","lineage":["https://openalex.org/I4210103180"]},{"id":"https://openalex.org/I83558840","display_name":"Universidade Nova de Lisboa","ror":"https://ror.org/02xankh89","country_code":"PT","type":"education","lineage":["https://openalex.org/I83558840"]}],"countries":["PT"],"is_corresponding":false,"raw_author_name":"Bruno A Cardoso","raw_affiliation_strings":["CEDOC, Faculdade de Ci\u00eancias M\u00e9dicas, Universidade Nova de Lisboa, Lisboa, Portugal","Instituto Portugu\u00eas de Oncologia de Lisboa Francisco Gentil, E.P.E, Lisboa, Portugal"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"CEDOC, Faculdade de Ci\u00eancias M\u00e9dicas, Universidade Nova de Lisboa, Lisboa, Portugal","institution_ids":["https://openalex.org/I83558840"]},{"raw_affiliation_string":"Instituto Portugu\u00eas de Oncologia de Lisboa Francisco Gentil, E.P.E, Lisboa, Portugal","institution_ids":["https://openalex.org/I4210103180"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5053192479","display_name":"H\u00e9lio Belo","orcid":"https://orcid.org/0000-0001-7626-9442","observed_orcids":["https://orcid.org/0000-0001-7626-9442"]},"institutions":[{"id":"https://openalex.org/I4210103180","display_name":"Instituto Portugu\u00eas de Oncologia Francisco Gentil","ror":"https://ror.org/00r7b5b77","country_code":"PT","type":"healthcare","lineage":["https://openalex.org/I4210103180"]},{"id":"https://openalex.org/I83558840","display_name":"Universidade Nova de Lisboa","ror":"https://ror.org/02xankh89","country_code":"PT","type":"education","lineage":["https://openalex.org/I83558840"]}],"countries":["PT"],"is_corresponding":false,"raw_author_name":"Helio Belo","raw_affiliation_strings":["CEDOC, Faculdade de Ci\u00eancias M\u00e9dicas, Universidade Nova de Lisboa, Lisboa, Portugal","Instituto Portugu\u00eas de Oncologia de Lisboa Francisco Gentil, E.P.E, Lisboa, Portugal"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"CEDOC, Faculdade de Ci\u00eancias M\u00e9dicas, Universidade Nova de Lisboa, Lisboa, Portugal","institution_ids":["https://openalex.org/I83558840"]},{"raw_affiliation_string":"Instituto Portugu\u00eas de Oncologia de Lisboa Francisco Gentil, E.P.E, Lisboa, Portugal","institution_ids":["https://openalex.org/I4210103180"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5083321170","display_name":"Ana Isabel Oliveira","orcid":"https://orcid.org/0000-0002-3160-6596","observed_orcids":["https://orcid.org/0000-0002-3160-6596"]},"institutions":[{"id":"https://openalex.org/I83558840","display_name":"Universidade Nova de Lisboa","ror":"https://ror.org/02xankh89","country_code":"PT","type":"education","lineage":["https://openalex.org/I83558840"]}],"countries":["PT"],"is_corresponding":false,"raw_author_name":"Ana Isabel Oliveira","raw_affiliation_strings":["CEDOC, Faculdade de Ci\u00eancias M\u00e9dicas, Universidade Nova de Lisboa, Lisboa, Portugal"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"CEDOC, Faculdade de Ci\u00eancias M\u00e9dicas, Universidade Nova de Lisboa, Lisboa, Portugal","institution_ids":["https://openalex.org/I83558840"]}]},{"author_position":"middle","author":{"id":null,"display_name":"Olga Pereira","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I83558840","display_name":"Universidade Nova de Lisboa","ror":"https://ror.org/02xankh89","country_code":"PT","type":"education","lineage":["https://openalex.org/I83558840"]}],"countries":["PT"],"is_corresponding":false,"raw_author_name":"Olga Pereira","raw_affiliation_strings":["CEDOC, Faculdade de Ci\u00eancias M\u00e9dicas, Universidade Nova de Lisboa, Lisboa, Portugal"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"CEDOC, Faculdade de Ci\u00eancias M\u00e9dicas, Universidade Nova de Lisboa, Lisboa, Portugal","institution_ids":["https://openalex.org/I83558840"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5038469796","display_name":"Jo\u00e3o Taborda Barata","orcid":"https://orcid.org/0000-0002-4826-8976","observed_orcids":["https://orcid.org/0000-0002-4826-8976"]},"institutions":[{"id":"https://openalex.org/I141596103","display_name":"University of Lisbon","ror":"https://ror.org/01c27hj86","country_code":"PT","type":"education","lineage":["https://openalex.org/I141596103"]},{"id":"https://openalex.org/I4392738257","display_name":"Instituto de Medicina Molecular Jo\u00e3o Lobo Antunes","ror":"https://ror.org/019g8w217","country_code":"PT","type":"facility","lineage":["https://openalex.org/I141596103","https://openalex.org/I4392738257","https://openalex.org/I4405252639"]}],"countries":["PT"],"is_corresponding":false,"raw_author_name":"Joao T Barata","raw_affiliation_strings":["Instituto de Medicina Molecular, Faculdade de Medicina da Universidade de Lisboa, Lisbon, Portugal"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Instituto de Medicina Molecular, Faculdade de Medicina da Universidade de Lisboa, Lisbon, Portugal","institution_ids":["https://openalex.org/I141596103","https://openalex.org/I4392738257"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5052287429","display_name":"Antonio Medina Almeida","orcid":"https://orcid.org/0000-0003-4361-0928","observed_orcids":["https://orcid.org/0000-0003-4361-0928"]},"institutions":[{"id":"https://openalex.org/I4210103180","display_name":"Instituto Portugu\u00eas de Oncologia Francisco Gentil","ror":"https://ror.org/00r7b5b77","country_code":"PT","type":"healthcare","lineage":["https://openalex.org/I4210103180"]},{"id":"https://openalex.org/I83558840","display_name":"Universidade Nova de Lisboa","ror":"https://ror.org/02xankh89","country_code":"PT","type":"education","lineage":["https://openalex.org/I83558840"]}],"countries":["PT"],"is_corresponding":false,"raw_author_name":"Antonio Almeida","raw_affiliation_strings":["CEDOC, Faculdade de Ci\u00eancias M\u00e9dicas, Universidade Nova de Lisboa, Lisboa, Portugal","Instituto Portugu\u00eas de Oncologia de Lisboa Francisco Gentil, E.P.E, Lisboa, Portugal"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"CEDOC, Faculdade de Ci\u00eancias M\u00e9dicas, Universidade Nova de Lisboa, Lisboa, Portugal","institution_ids":["https://openalex.org/I83558840"]},{"raw_affiliation_string":"Instituto Portugu\u00eas de Oncologia de Lisboa Francisco Gentil, E.P.E, Lisboa, Portugal","institution_ids":["https://openalex.org/I4210103180"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":4,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":{"value":5500,"currency":"USD","value_usd":5500},"apc_paid":null,"fwci":0.4245,"has_fulltext":false,"cited_by_count":2,"citation_normalized_percentile":{"value":0.64266775,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":89,"max":94},"biblio":{"volume":"124","issue":"21","first_page":"910","last_page":"910"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11628","display_name":"Myeloproliferative Neoplasms: Diagnosis and Treatment","score":0.9965999722480774,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T11628","display_name":"Myeloproliferative Neoplasms: Diagnosis and Treatment","score":0.9965999722480774,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10309","display_name":"Acute Myeloid Leukemia Research","score":0.0010000000474974513,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11215","display_name":"Chronic Myeloid Leukemia Treatments","score":0.00039999998989515007,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/bcr-abl-negative-myeloproliferative-neoplasms","display_name":"BCR-ABL-negative myeloproliferative neoplasms","score":0.9869999885559082},{"id":"https://openalex.org/keywords/bone-marrow-stroma","display_name":"bone marrow stroma","score":0.9869999885559082},{"id":"https://openalex.org/keywords/ruxolitinib","display_name":"ruxolitinib","score":0.7749999761581421},{"id":"https://openalex.org/keywords/vorinostat","display_name":"vorinostat","score":1.0},{"id":"https://openalex.org/keywords/drug-resistance","display_name":"drug resistance","score":0.7720000147819519},{"id":"https://openalex.org/keywords/apoptosis","display_name":"apoptosis","score":0.9309999942779541},{"id":"https://openalex.org/keywords/jak-stat-signaling","display_name":"JAK/STAT signaling","score":0.7749999761581421},{"id":"https://openalex.org/keywords/pi3k-akt-mtor-pathway","display_name":"PI3K/AKT/mTOR pathway","score":0.8820000290870667},{"id":"https://openalex.org/keywords/mek-erk-signaling","display_name":"MEK/ERK signaling","score":0.7699999809265137},{"id":"https://openalex.org/keywords/nf-kappab-signaling","display_name":"NF-\u03baB signaling","score":0.8220000267028809},{"id":"https://openalex.org/keywords/mapk-jnk-signaling","display_name":"MAPK/JNK signaling","score":0.8989999890327454},{"id":"https://openalex.org/keywords/histone-deacetylase-inhibitors","display_name":"histone deacetylase inhibitors","score":0.8460000157356262},{"id":"https://openalex.org/keywords/jak-inhibitors","display_name":"JAK inhibitors","score":0.6320000290870667}],"concepts":[{"id":"https://openalex.org/C2776112149","wikidata":"https://www.wikidata.org/wiki/Q7383611","display_name":"Ruxolitinib","level":4,"score":0.7794205546379089},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.6557770371437073},{"id":"https://openalex.org/C2780007613","wikidata":"https://www.wikidata.org/wiki/Q546523","display_name":"Bone marrow","level":2,"score":0.6306209564208984},{"id":"https://openalex.org/C2776262904","wikidata":"https://www.wikidata.org/wiki/Q905901","display_name":"Vorinostat","level":5,"score":0.5891887545585632},{"id":"https://openalex.org/C109159458","wikidata":"https://www.wikidata.org/wiki/Q919283","display_name":"Haematopoiesis","level":3,"score":0.4925873875617981},{"id":"https://openalex.org/C2781107747","wikidata":"https://www.wikidata.org/wiki/Q1898104","display_name":"Myeloproliferative neoplasm","level":4,"score":0.49173954129219055},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.4639551043510437},{"id":"https://openalex.org/C2780225316","wikidata":"https://www.wikidata.org/wiki/Q7131441","display_name":"Panobinostat","level":5,"score":0.4600209593772888},{"id":"https://openalex.org/C117262875","wikidata":"https://www.wikidata.org/wiki/Q5135057","display_name":"Clonogenic assay","level":3,"score":0.42581555247306824},{"id":"https://openalex.org/C203014093","wikidata":"https://www.wikidata.org/wiki/Q101929","display_name":"Immunology","level":1,"score":0.36570000648498535},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.35148799419403076},{"id":"https://openalex.org/C2780076729","wikidata":"https://www.wikidata.org/wiki/Q1752571","display_name":"Myelofibrosis","level":3,"score":0.2848222851753235},{"id":"https://openalex.org/C2778305200","wikidata":"https://www.wikidata.org/wiki/Q174378","display_name":"Histone deacetylase","level":4,"score":0.2752908766269684},{"id":"https://openalex.org/C28328180","wikidata":"https://www.wikidata.org/wiki/Q48196","display_name":"Stem cell","level":2,"score":0.22101619839668274},{"id":"https://openalex.org/C1491633281","wikidata":"https://www.wikidata.org/wiki/Q7868","display_name":"Cell","level":2,"score":0.17240998148918152},{"id":"https://openalex.org/C64927066","wikidata":"https://www.wikidata.org/wiki/Q36293","display_name":"Histone","level":3,"score":0.0869782567024231},{"id":"https://openalex.org/C95444343","wikidata":"https://www.wikidata.org/wiki/Q7141","display_name":"Cell biology","level":1,"score":0.08369633555412292},{"id":"https://openalex.org/C104317684","wikidata":"https://www.wikidata.org/wiki/Q7187","display_name":"Gene","level":2,"score":0.0},{"id":"https://openalex.org/C54355233","wikidata":"https://www.wikidata.org/wiki/Q7162","display_name":"Genetics","level":1,"score":0.0},{"id":"https://openalex.org/C55493867","wikidata":"https://www.wikidata.org/wiki/Q7094","display_name":"Biochemistry","level":1,"score":0.0}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1182/blood.v124.21.910.910","doi":"https://doi.org/10.1182/blood.v124.21.910.910","is_oa":false,"landing_page_url":"https://doi.org/10.1182/blood.v124.21.910.910","pdf_url":null,"source":{"id":"https://openalex.org/S200071133","display_name":"Blood","issn_l":"0006-4971","issn":["0006-4971","1528-0020"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Blood","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","score":1.0,"display_name":"Good health and well-being"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2262537071","https://openalex.org/W7099348025","https://openalex.org/W2530832837","https://openalex.org/W2013377223","https://openalex.org/W2797414363","https://openalex.org/W4310117644","https://openalex.org/W2913808284","https://openalex.org/W2101002658","https://openalex.org/W2768585710","https://openalex.org/W1605054135"],"abstract_inverted_index":{"Abstract":[0],"Background:":[1],"The":[2,53,300],"classical":[3],"BCR-ABL-negative":[4],"myeloproliferative":[5],"neoplasms":[6],"(MPN)":[7],"are":[8],"characterized":[9],"by":[10,158,208,241,368,478,497],"increased":[11,369],"proliferation":[12,339,451],"of":[13,24,35,38,55,62,69,115,193,196,235,248,261,289,293,319,331,352,371,398,404,419,432,445,459,466,493,522],"hematopoietic":[14],"precursors":[15],"in":[16,21,32,59,84,89,112,122,140,190,286,328,487,526],"the":[17,29,33,36,60,67,101,113,129,137,146,149,191,219,249,287,317,320,350,395,417,430,446,456,467,484,491,494,498,507,520],"bone":[18,50,150,182,388,447,499,508],"marrow":[19,51,151,183,389,448,500,509],"resulting":[20],"elevated":[22],"numbers":[23],"terminally":[25],"differentiated":[26],"cells.":[27,165,469],"Despite":[28],"recent":[30],"advances":[31],"understanding":[34],"biology":[37],"MPN,":[39],"there":[40],"is":[41,124,413,462],"still":[42],"no":[43],"curative":[44],"treatment":[45,114],"for":[46,49,230,246,306,356],"MPN":[47,63,73,90,123,141,169,216,282,329,392,488,511],"except":[48],"transplantation.":[52],"discovery":[54],"JAK-STAT":[56,363],"constitutive":[57],"activation":[58,351,431],"majority":[61],"patients":[64],"led":[65],"to":[66,95,135,155,308,463,482,504],"development":[68],"clinical":[70],"studies":[71],"targeting":[72],"with":[74,180,186,210,266,325,334,349],"Ruxolitinib,":[75],"a":[76,290,473],"JAK1/2-specific":[77],"inhibitor.":[78],"However,":[79],"despite":[80],"achieving":[81],"significant":[82],"reductions":[83],"splenomegaly":[85],"and":[86,99,128,167,175,198,212,226,257,263,269,273,312,338,348,364,380,408,427,513,524],"symptomatic":[87],"improvement":[88],"patients,":[91],"JAK":[92],"inhibition":[93],"failed":[94],"induce":[96],"complete":[97],"remissions":[98],"eradicate":[100,136,483],"malignant":[102],"clone.":[103],"In":[104],"alternative,":[105],"histone":[106],"deacetylase":[107],"inhibitors":[108],"have":[109],"shown":[110,367],"success":[111],"several":[116],"hematological":[117],"malignancies":[118],"but":[119],"their":[120,160],"efficacy":[121],"limited.":[125],"Aims:":[126],"Ruxolitinib":[127,197,270,480,523],"HDAC":[130],"inhibitor":[131],"Vorinostat":[132,268,407,525],"both":[133,267],"fail":[134],"neoplastic":[138,164,468,485],"clone":[139,486],"patients.":[142,489],"Here,":[143],"we":[144,385,502],"tested":[145],"hypothesis":[147],"that":[148,387,421,455],"stroma":[152,184,301,390,449],"confers":[153],"resistance":[154],"these":[156],"drugs":[157],"preventing":[159],"cytotoxic":[161,396],"effects":[162,323,397,444],"on":[163,316,450],"Material":[166],"Methods:":[168],"patient":[170],"derived":[171],"cell":[172,475],"lines":[173],"(SET-2":[174],"HEL)":[176],"were":[177,224,284],"cultured":[178,285],"alone,":[179],"HS-5":[181,187,220,294,297],"or":[185,296,452],"conditioned":[188,298],"medium":[189],"presence":[192,288],"clinically-relevant":[194],"concentrations":[195],"Vorinostat.":[199],"At":[200],"different":[201,405],"time":[202],"points,":[203],"cellular":[204,357],"viability":[205],"was":[206,228,239,278,304,313],"analyzed":[207],"staining":[209],"Annexin-V/PI":[211],"CD45-APC":[213],"(to":[214],"distinguish":[215],"cells":[217,223,265,283,295,330,393,461,512],"from":[218,394],"cells).":[221],"Furthermore,":[222],"lysed":[225],"RNA":[227],"extracted":[229],"gene":[231],"expression":[232,327],"analysis.":[233],"Activation":[234],"specific":[236],"signaling":[237,251,353,434],"pathways":[238,354,435],"determined":[240],"Western-blot":[242],"using":[243],"phospho-specific":[244],"antibodies":[245],"effectors":[247],"following":[250],"pathways:":[252],"PI3K-Akt-mTOR;":[253],"MEK-Erk;":[254],"MAPK-JNK;":[255],"NF-\u03baB":[256,365],"JAK-STAT.":[258],"Results:":[259],"Treatment":[260],"SET-2":[262],"HEL":[264],"promoted":[271],"apoptosis":[272,277,337,423,465],"decreased":[274],"proliferation.":[275],"Importantly,":[276],"significantly":[279],"abrogated":[280],"when":[281],"stromal":[291,460],"layer":[292],"medium.":[299],"protective":[302,411],"effect":[303,412,458],"maintained":[305],"up":[307],"6":[309],"six":[310],"days":[311],"also":[314,428],"dependent":[315],"concentration":[318],"drugs.":[321],"These":[322],"correlated":[324],"altered":[326],"genes":[332,420],"associated":[333],"inflammatory":[335],"processes,":[336],"(CDKN1A,":[340],"IER3,":[341],"BIRC3,":[342],"TNFRSF8,":[343,425],"TNFRSF9,":[344],"COX2,":[345],"IL1B,":[346],"XIAP),":[347],"important":[355],"homeostasis,":[358],"such":[359,436],"as":[360,366,437],"PI3K-Akt-mTOR,":[361],"MAPK-JNK,":[362],"phosphorylation":[370],"Akt":[372],"(Ser473);":[373],"GSK3\u03b1/\u03b2":[374],"(Ser9/Ser21);":[375],"S6":[376],"(Ser235/236);":[377],"STAT3/5":[378],"(Tyr705/Tyr694)":[379],"IKB\u03b1":[381],"(Ser32).":[382],"Summary/Conclusions:":[383],"Overal,":[384],"show":[386],"protects":[391,510],"two":[399],"clinically":[400],"effective":[401],"pharmacological":[402],"agents":[403],"classes:":[406],"Ruxolitinib.":[409],"This":[410],"likely":[414],"achieved,":[415],"through":[416,429],"up-regulation":[418],"inhibit":[422],"(BIRC3,":[424],"TNFRSF9)":[426],"pro-survival":[433],"PI3K-Akt-mTOR.":[438],"We":[439],"did":[440],"not":[441],"observe":[442],"any":[443],"differentiation,":[453],"suggesting":[454],"main":[457],"prevent":[464],"Our":[470],"results":[471],"identify":[472],"possible":[474],"non-autonomous":[476],"mechanism":[477],"which":[479],"fails":[481],"Through":[490],"identification":[492],"factors":[495],"released":[496],"stroma,":[501],"hope":[503],"uncover":[505],"why":[506],"possibly":[514],"define":[515],"novel":[516],"therapeutic":[517],"strategies":[518],"maximizing":[519],"use":[521],"MPN.":[527],"Disclosures":[528],"Almeida:":[529],"Shire:":[530],"Speakers":[531,534,542],"Bureau;":[532,535],"Amgen:":[533],"Novartis:":[536],"Consultancy;":[537,539],"Celgene:":[538],"Bristol-Meyer":[540],"Squibb:":[541],"Bureau.":[543]},"counts_by_year":[{"year":2017,"cited_by_count":1},{"year":2016,"cited_by_count":1}],"updated_date":"2026-11-04T10:54:05.112534","created_date":"2017-02-17T00:00:00"}